Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.53 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657467 | 0.91 | PGR (0.50) | PGRNR3C1NR3C2ESR1ESR2 | |
| SCHEMBL3655517 | 0.88 | PGR (0.53) | PGRNR3C1NR3C2SLC13A5ESR1 | |
| SCHEMBL3657144 | 0.85 | KMT2A (0.49) | PGRNR3C1NR3C2RAB9ALMNA | |
| SCHEMBL4133085 | 0.82 | CYP2C19 (0.47) | PGRNR3C1NR3C2SLC13A5ALDH1A1 | |
| SCHEMBL3687265 | 0.82 | NR3C1 (0.57) | PGRNR3C1NR3C2SLC13A5 | |
| SCHEMBL3681100 | 0.81 | PGR (0.55) | PGRNR3C1NR3C2ESR1ESR2 | |
| SCHEMBL3655713 | 0.79 | PGR (0.57) | PGRNR3C1NR3C2 | |
| SCHEMBL3656436 | 0.78 | PGR (0.41) | PGRNR3C1NR3C2SLC13A5RAB9A | |
| SCHEMBL5518377 | 0.77 | NR3C1 (0.50) | PGRNR3C1NR3C2ESR1ESR2 | |
| SCHEMBL4618221 | 0.77 | PGR (0.54) | PGRNR3C1NR3C2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1895999-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Schering Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | claimed |
| US-7189758-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | claimed |
| WO-2007022824-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | WO | claimed |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1467982-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2006-11-22 | — | — | EP | claimed |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | claimed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| EP-2056799-B1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2203160-B1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | BAUSCH & LOMB (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2190431-B1 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | BAUSCH & LOMB (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2364707-B1 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| EP-2397140-A1 | Compositions and methods for treating or preventing glaucoma or progression thereof | BAUSCH & LOMB INCORPORATED (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1467982-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6960581-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1467982-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, NR3C2, MC2R | PGR 227/4885NR3C1 1/4885NR3C2 2/4885 |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | SHBG, PGR, NR5A1 | PGR 2/4885NR3C1 32/4885NR3C2 17/4885 |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, MC2R, NR3C2 | PGR 80/4885NR3C1 1/4885NR3C2 3/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | PGR 220/4885NR3C1 3/4885NR3C2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.